TAMPA, FL -- Saying their industry is facing unprecedented pricing pressures, manufacturers of generics and biosimilars are pressing Congress to support policies they say would both benefit them and avert future shortages, like acting on pharmacy benefit manager (PBM) reform and repealing a Medicaid penalty for price increases. At the Association for Accessible Medicines (AAM) annual meeting in Tampa, FL this week, officials with the generics and biosimilars lobbying group told Inside Health Policy lawmakers striving to address high...